scispace - formally typeset
E

Eva Harris

Researcher at University of California, Berkeley

Publications -  357
Citations -  26475

Eva Harris is an academic researcher from University of California, Berkeley. The author has contributed to research in topics: Dengue virus & Dengue fever. The author has an hindex of 84, co-authored 332 publications receiving 22718 citations.

Papers
More filters
Journal ArticleDOI

Zika Virus Nonstructural Protein 1 Disrupts Glycosaminoglycans and Causes Permeability in Developing Human Placentas.

TL;DR: It is suggested that ZIKV NS1 contributes to placental dysfunction via modulation of glycosaminoglycans on trophoblasts and chorionic villi, resulting in increased permeability of human placentas.
Journal ArticleDOI

Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua

TL;DR: It is shown that the age at which children acquired DENV-specific immunity more than doubled during the observational period of a pediatric cohort study in Managua, Nicaragua, and that the overall gradual decline in the FoI can be attributed to demographic shifts.
Journal ArticleDOI

Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections

TL;DR: This study demonstrates the association between preinfection anti-DENV antibody titer, serum viral load, and disease severity, and provides evidence for the mechanism of antibody-dependent enhancement in dengue cases.
Journal ArticleDOI

Mobilising communities for Aedes aegypti control: the SEPA approach.

TL;DR: The SEPA concept and its theoretical origins are explained, giving examples of its previous application in different countries and contexts, and details that show commonalities and differences in the application of the approach in Mexico and Nicaragua are described.
Journal ArticleDOI

Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.

TL;DR: It is demonstrated here that goose-derived anti-DENV2 IgY neutralized DENV2 and did not induce ADE in vitro, and was also protective in vivo when administered 24 hours following a lethal, antibody-enhanced infection.